BOULDER, Colo. --(BUSINESS WIRE)--May 17, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton , Chief Executive Officer of Biodesix , will present virtually at the H.C.

BOULDER, Colo. --(BUSINESS WIRE)--May 12, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in

First quarter 2022 core Lung Diagnostic revenue of $4.6 million increased 17% over the comparable period in 2021; Continued to strengthen financial position through an additional $27.4 million in debt and equity funding during second quarter 2022; Conference Call and Webcast Today at 8:00 a.m.

BOULDER, Colo. --(BUSINESS WIRE)--Apr. 27, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2022 before the open of trading on

Approximately $11.7 million in Common Shares Sold Under a Private Placement Third Amendment to 2021 Term Loan Provides Additional Financial Flexibility for Growth BOULDER, Colo. --(BUSINESS WIRE)--Apr. 11, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with

Additionally, data associated with the GeneStrat ® ddPCR ™ and Genestrat NGS ™ blood tests will be presented at the American Association for Cancer Research (AACR) BOULDER, Colo. --(BUSINESS WIRE)--Mar. 29, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company

Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods, respectively Full-Scale Launch of GeneStrat NGS™ Test in January 2022 Conference Call and Webcast Today at 8:30 a.m. ET BOULDER, Colo.

BOULDER, Colo. --(BUSINESS WIRE)--Mar. 7, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has entered into a purchase agreement for the issuance and sale of its common stock, from time to time, of up to $50

BOULDER, Colo. --(BUSINESS WIRE)--Mar. 3, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting.

BOULDER, Colo. --(BUSINESS WIRE)--Mar. 1, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton , Chief Executive Officer of Biodesix , will present at Cowen’s 42nd Annual Healthcare Conference being held